France
-
Cyllene Therapeutics secures US$37.8 M to advance gene therapy for severe neurogenic bladder disorders
The financing round was co-led by M Ventures, the venture capital arm of Merck KGaA, and GordonMD Global Investments.
-
Ipsen acquires Memo Therapeutics for US$798.4M to secure Potravitug
The acquisition centres on potravitug, a Phase II monoclonal antibody developed to treat BK polyomavirus-associated nephropathy (BKPyVAN).
-
BrightHeart secures EU regulatory clearance for prenatal screening AI
BrightHeart will officially introduce the platform to European clinicians during the Fetal Medicine Foundation (FMF) World Congress in Vienna, taking place from June 28 to July 2, 2026.
-
Kenya unveils major push for local vaccine manufacturing as French Minister visits BioVax Institute
The next phase will focus on installing and validating fill-and-finish equipment, strengthening quality control systems, building specialized workforce capacity, and preparing for compliant vaccine manufacturing.
-
Jeito Capital closes USD1.2B second fund to support European biopharma breakthroughs
Jeito II will back between 15 and 20 clinical-stage biopharma companies, primarily in Europe, with average investments of up to €150 million (USD180 million) per company
-
Africa CDC secures USD310M strategic investment at Lyon One Health Summit
Implementing these programs under Africa CDC leadership will enhance disease surveillance systems, expand laboratory infrastructure, and foster deeper partnerships with leading European research institutions.
-
SK Pharmteco establishes advanced viral vector manufacturing facility in France
The site can produce up to 40 CGMP batches annually, supporting parallel processing for multiple client programs and ensuring reliable supply chains.
-
Valneva to close Nantes facility, centralizing R&D in Vienna following lower sales forecast
The closure announcement follows Valneva’s financial results for the first nine months of 2025, which revealed mixed performance.
-
Axoltis Pharma secures USD20.9 million in series A funding to advance ALS drug development
The total USD20.9 million funding will be divided into two tranches, with the release of the second contingent on outcomes from the ongoing ‘SEALS’ phase 2 clinical trial.